Table of Contents Author Guidelines Submit a Manuscript
Advances in Bioinformatics
Volume 2016, Article ID 7053712, 11 pages
http://dx.doi.org/10.1155/2016/7053712
Research Article

Efficacy and Toxicity Assessment of Different Antibody Based Antiangiogenic Drugs by Computational Docking Method

1Department of Physiology, West Bengal State University, Berunanpukuria, Malikapur, Barasat, Kolkata 700 126, India
2Society for Systems Biology & Translational Research, No. 103, Block C, Bangur Avenue, Kolkata 700 055, India

Received 30 November 2015; Accepted 21 January 2016

Academic Editor: Huixiao Hong

Copyright © 2016 Sayan Mukherjee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. H. Ausprunk and J. Folkman, “Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis,” Microvascular Research, vol. 14, no. 1, pp. 53–65, 1977. View at Publisher · View at Google Scholar · View at Scopus
  2. W. Risau, “Mechanisms of angiogenesis,” Nature, vol. 386, no. 6626, pp. 671–674, 1997. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Schettino, M. A. Bareschino, V. Ricci, and F. Ciardiello, “Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment,” Expert Review of Respiratory Medicine, vol. 2, no. 2, pp. 167–178, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. J.-M. Lee, G. A. Sarosy, C. M. Annunziata et al., “Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity,” British Journal of Cancer, vol. 102, no. 3, pp. 495–499, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Banerjee, M. Dowsett, A. Ashworth, and L.-A. Martin, “Mechanisms of Disease: angiogenesis and the management of breast cancer,” Nature Clinical Practice Oncology, vol. 4, no. 9, pp. 536–550, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. E. A. Donovan and S. Kummar, “Targeting VEGF in cancer therapy,” Current Problems in Cancer, vol. 30, no. 1, pp. 7–32, 2006. View at Publisher · View at Google Scholar
  7. F. Gurevich and M. A. Perazella, “Renal effects of anti-angiogenesis therapy: update for the internist,” The American Journal of Medicine, vol. 122, no. 4, pp. 322–328, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Hapani, D. Chu, and S. Wu, “Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis,” The Lancet Oncology, vol. 10, no. 6, pp. 559–568, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. S. S. Shord, L. R. Bressler, L. A. Tierney, S. Cuellar, and A. George, “Understanding and managing the possible adverse effects associated with bevacizumab,” American Journal of Health-System Pharmacy, vol. 66, no. 11, pp. 999–1013, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Ribatti, V. Longo, and A. Vacca, “Antiangiogenic treatment of hematological tumors,” in Anti-Angiogenesis Drug Discovery and Development, A. Rahman and M. I. Choudhary, Eds., vol. 1, pp. 1–11, Bentham Science, Sharjah, UAE, 2011. View at Google Scholar
  11. CenterWatch Drug Information Herceptin, 2010, http://www.centerwatch.com/drug-information/fda-approved-drugs/year/2010.
  12. Funakoshi, Japan, 2015, http://www.funakoshi.co.jp/data/datasheet/ABD/HCA176.pdf.
  13. National Cancer Institute, FDA Approval for Trastuzumab, 2015, http://www.cancer.gov/about-cancer/treatment/drugs/fda-trastuzumab.
  14. Genentech, “FDA full precribing information, warnings and precautions,” 2010, http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdf.
  15. S. Mukherjee and D. Majumder, “Computational molecular docking assessment of hormone receptor adjuvant drugs: breast cancer as an example,” Pathophysiology, vol. 16, no. 1, pp. 19–29, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Majumder and S. Mukherjee, “Molecular docking assessment of efficacy of different clinically used arsenic chelator drugs,” Journal of Computational Medicine, vol. 2013, Article ID 396768, 8 pages, 2013. View at Publisher · View at Google Scholar
  17. H. M. Berman, J. Westbrook, Z. Feng et al., “The protein data bank,” Nucleic Acids Research, vol. 28, no. 1, pp. 235–242, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. D. S. Wishart, C. Knox, A. C. Guo et al., “DrugBank: a comprehensive resource for in silico drug discovery and exploration,” Nucleic Acids Research, vol. 34, supplement 1, pp. D668–D672, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Das and D. Majumder, “Interactions among MARM binding factors,” in Proceedings of the World Congress on Information and Communication Technologies (WICT '12), A. Abraham, S. M. Thampi, S. Pal et al., Eds., pp. 191–196, Trivandrum, India, October-November 2012. View at Publisher · View at Google Scholar
  20. B. Das and D. Majumder, “Interactions of transcription factors in HLA class I transcriptosome,” International Journal of Computer Information Systems, vol. 6, pp. 592–602, 2014. View at Google Scholar
  21. D. Ritchie, “Hex 8.0.0 user manual,” 1996, http://hex.loria.fr/manual800/hex_manual.pdf.
  22. A. Mukherjee and D. Majumder, “Dynamical model for assessment of anti-angiogenic therapy of cancer,” Molecular BioSystems, vol. 6, no. 6, pp. 1047–1055, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. P. K. Dhar and D. Majumder, “A composite synergistic systems model for exploring the efficacies of different chemotherapeutic strategies in cancer,” Computational Biology Journal, vol. 2013, Article ID 301369, 26 pages, 2013. View at Publisher · View at Google Scholar
  24. D. Majumder and A. Mukherjee, “Patho-physiologically based logistics for treatment of cancer,” Journal of Biological Systems, vol. 14, no. 4, pp. 631–650, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. D. Majumder and A. Mukherjee, “Multi-scale modeling approaches in systems biology towards the assessment of cancer treatment dynamics: adoption of middle-out rationalist approach,” Advances in Cancer Research & Treatment, vol. 2013, Article ID 587889, 26 pages, 2013. View at Publisher · View at Google Scholar
  26. D. Majumder and A. Mukherjee, “Mathematical modelling of toxicity-related trade-offs in metronomic chemotherapy,” IET Systems Biology, vol. 1, no. 5, pp. 298–305, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. O. Wolkenhauer, “Defining systems biology: an engineering perspective,” IET Systems Biology, vol. 1, no. 4, pp. 204–206, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Mukherjee and D. Majumder, “Mathematical modelling for the assessment of the effect of drug application delays in metronomic chemotherapy of cancer due to physiological constraints,” BioSystems, vol. 91, no. 1, pp. 108–116, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. D. Majumder and A. Mukherjee, “A passage through systems biology to systems medicine: adoption of middle-out rational approaches towards the understanding of clinical outcome in cancer therapy,” Analyst, vol. 136, no. 4, pp. 663–678, 2011. View at Publisher · View at Google Scholar
  30. D. Majumder, “Assessment for possible drug application delays in MCT strategy due to pathophysiological constraints of cancer,” in Proceedings of the IEEE World Congress on Information and Communication Technologies (WICT '12), A. Abraham, S. M. Thampi, S. Pal et al., Eds., Paper 233, IEEE Catalog Number: CFP1268R-CDR, pp. 4673–4804, Trivandrum, India, October-November 2012.